Study on efficacy and prognosis of dapagliflozin combined with sacubitril valsartan in treating non-reduced ejection fraction type heart failure
10.3969/j.issn.1671-8348.2025.02.023
- VernacularTitle:达格列净联合沙库巴曲缬沙坦治疗非射血分数降低型心力衰竭的疗效及预后研究
- Author:
Xiaogang YANG
1
;
Jiandong XING
;
Yun ZHANG
;
Yulong XING
Author Information
1. 南京市高淳人民医院/江苏卫生健康职业学院附属南京市高淳人民医院心内科,南京 211300
- Keywords:
non-reduced ejection fraction heart failure;
sacubitril-valsartan;
dapagliflozin;
N-terminal B-type natriuretic peptide precursor;
6 min walk test;
major adverse cardiovascular events
- From:
Chongqing Medicine
2025;54(2):425-429
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of dapagliflozin combined with sacubitril-valsar-tan in the treatment of non-reduced ejection fraction type heart failure(non-HFrEF).Methods A total of 120 patients with non-HFrEF diagnosed and treated in this hospital from January to December 2022 were selected as the study subjects and divided into the observation group and control group by the random number method,60 cases in each group.The both groups were treated with conventional treatments such as β-receptor blockers and diuretics,the patients in the control group were treated with sacubitril-valsartan(Noxinto),and the pa-tients in the observation group were treated with dapagliflozin on the basis of the control group for 6 months.The clinical efficacy,serum N-terminal B-type natriuretic peptide precursor(NT-proBNP),hypersensitivity-C-reactive protein(hs-CRP),serum creatinine(SCr),serum potassium,cardiac color Doppler ultrasound param-eters,6 min walk test(6MWT)distance before treatment and in 6 months after treatment,and the occurrence of major adverse cardiovascular events(MACE)during treatment were compared between the two groups.Re-sults After 6 months of treatment,the total effective rate in the observation group was 93.3%,which was higher than 80%in the control group,and the difference was statistically significant(P=0.032).After 6 months of treatment,the levels of NT-proBNP and hs-CRP in the two groups were significantly decreased compared with those before treatment,moreover the observation group was lower than the control group,and the difference was statistically significant(P<0.05).After 6 months of treatment,LVEF and 6MWT dis-tance in the two groups were increased compared with those before treatment,LVEDV and LVESV were de-creased compared with those before treatment,moreover the change amplitude of the above indexes in the ob-servation group were greater than those in the control group,and the differences were statistically significant(P<0.05).The incidence rate of MACE in the observation group was lower than that in the control group(16.7%vs.5.0%),and the difference was statistically significant(P<0.05).Conclusion Dapagliflozin combined with sacubitril-valsartan in the treatment of non-HFrEF could significantly reduce the levels of NT-proBNP and hs-CRP,improve the cardiac function,increase the exercise tolerance,decrease the incidence rate of MACE and improve the prognosis.
